27 January 2009: NorDiag has appointed DiaTech SRL as exclusive distributor in the field of infectious diseases for Italy.

DiaTech SRL is an integrated biotechnology company involved in R&D, production and distribution of reagents, kits and instruments for molecular biology, virology, cell biology, microbiology, clinical diagnostic and immunology. The company has grown to become a strong and established player in the Italian market with superior track records for distribution of clinical diagnostic products from well known companies. The company`s products are used by clinical laboratories, hospitals and leading research institutes. The company`s headquarters are in Jesi, Italy.

Mårten Wigstøl, CEO in NorDiag, comments: -`Since we successfully finalized our STI validation trials we have seen a strong sales growth in the range of 88 % in Q4-08 compared to Q3-08. With proven applications with large market potential and new applications in pipeline, we expect the growth to continue in 2009. The combination of strong growth and an exciting product portfolio enables us to attract superior distributors such as DiaTech.`

NorDiag has started to penetrate the European market with its instruments and reagents. The rights issue, which now is in the middle of the subscription period, will give the company financial strength to grow further internationally.  NorDiag has already established a solid foothold and market share in Scandinavia and the strategy is to use the Scandinavian market as a reference market for further commercialization and geographic expansion. DiaTech is expected to give a major contribution to this process, with their network, competence and industry knowledge.

Contact:             
CEO Mårten Wigstøl      
Phone: +47 911 65775 or
morten.wigstol@nordiag.com

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

Read the notice in Norwegian here